New Phosphorous Binder in Pipeline

Keryx biopharmaceuticals has announced that their new phosphorous binder Zerenex is well tolerated, safe and effective for long term use.

Zerenex (ferric citrate) is an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a U.S. Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and we are in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Zerenex is also in Phase 2 development in Japan.

Data from the mid-stage trial indicated that Zerenex could maintain phosphorus content at a normal level when used over an extended period of time. The data did not show signs of potential iron overload in the blood. The late-stage study for the kidney drug is expected to begin at the end of the year. More details to follow when available.